<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02607124</url>
  </required_header>
  <id_info>
    <org_study_id>CLEE011XUS17T</org_study_id>
    <nct_id>NCT02607124</nct_id>
  </id_info>
  <brief_title>A Phase I/II Study of Ribociclib,a CDK4/6 Inhibitor, Following Radiation Therapy</brief_title>
  <official_title>A Phase I/II Study of Ribociclib, a CDK4/6 Inhibitor, Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital Medical Center, Cincinnati</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this research study the investigators want to learn more about the effects, both good and&#xD;
      bad, when the study drug Ribociclib is given after radiation therapy.&#xD;
&#xD;
      The investigators are asking people to be in this research study that have been newly&#xD;
      diagnosed with a high grade glioma, and the tumor has been screened for the Rb1 protein, and&#xD;
      have recently finished radiation therapy. Patients with a DIPG or a Bi-thalamic high grade&#xD;
      glioma do not need to have tumor tissue screened for the Rb1 protein but do need to have&#xD;
      finished radiation therapy.&#xD;
&#xD;
      Tumor cells grow and divide quickly. In normal cells, there are proteins called&#xD;
      cyclin-dependent kinases (CDK 4 and 6) that control cell division. Another protein Rb1 also&#xD;
      controls cell division and works to stop cells from dividing so they do not become cancer&#xD;
      cells. But in cancer, the CDK 4 and 6 proteins are out of control making the cells divide and&#xD;
      grow quickly. The study drug, ribociclib stops the CDK 4 and 6 proteins. When the CDK 4 and 6&#xD;
      proteins are stopped, the normal Rb1 protein can now work to slow cell growth. For patients&#xD;
      with HGG, to be in this study tumor tissue must have a normal Rb1 protein. The researchers&#xD;
      think that if the study drug is given soon after radiation therapy, it may help improve the&#xD;
      effect of the radiation in stopping the tumor from growing.&#xD;
&#xD;
      The study drug, Ribociclib is considered investigational as it has not yet been approved by&#xD;
      the United States Food and Drug Administration. The study drug has been tested in children&#xD;
      and adults with cancer in prior research studies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ribociclib has shown an acceptable toxicity profile in adults and pediatrics. Available data&#xD;
      suggests that over 70% of DIPG patient have an intact RB and 90% HGG patients have expression&#xD;
      of RB, therefore CDK4/6 inhibition is a suitable target. Given the dismal prognosis for&#xD;
      children with DIPG and HGG, it is appropriate to evaluate the long term feasibility and early&#xD;
      efficacy of Ribociclib following radiation therapy in patients with RB+ tumors. The aim of&#xD;
      the upfront biopsy molecular studies proposed is to identify subgroups of patients who will&#xD;
      benefit from the use of checkpoint inhibitors in the setting of intact RB pathway. This study&#xD;
      will play a major role in moving the field of DIPG/HGG research forward as the investigators&#xD;
      intend to reveal feasibility of upfront stereotactic biopsy and specific pathway directed&#xD;
      therapy following radiation therapy with the ultimate goal to add additional targeted therapy&#xD;
      in combination with Ribociclib resulting in improving the outcome for patients diagnosed with&#xD;
      these fatal tumors.&#xD;
&#xD;
      The current proposal will be a novel pediatric study to obtain biopsy in DIPG prior to&#xD;
      therapy and administer molecularly targeted therapy following radiation therapy in children&#xD;
      with newly diagnosed DIPG and HGG. In this study, the investigators will assess the assess&#xD;
      long-term feasibility and early efficacy of Ribociclib administered daily for 3 weeks and off&#xD;
      one week every 28 days following radiation therapy for at least 6 courses and up to 12&#xD;
      courses in patients with newly-diagnosed non-biopsied DIPG and RB+ biopsied DIPG and HGG.&#xD;
      Moreover, the investigators will approach this devastating disease with a multi-disciplinary&#xD;
      team and evaluate the quality of life and functional outcome resulting in effective&#xD;
      interventions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    A competing trial was opened for patient population with combination of ribociclib and&#xD;
    everolimus.&#xD;
  </why_stopped>
  <start_date>April 2016</start_date>
  <completion_date type="Actual">August 2018</completion_date>
  <primary_completion_date type="Actual">May 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>6 months</time_frame>
    <description>Primary feasibility endpoint is the number of individual toxicities and incidence of significant delays</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients Alive at One Year</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>High Grade Glioma</condition>
  <condition>Diffuse Intrinsic Pontine Glioma</condition>
  <condition>Bithalamic High Grade Glioma</condition>
  <arm_group>
    <arm_group_label>RB+ High Grade Glioma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ribociclib administered orally; daily on days 1-21 each 28 day cycle; dose calculation age dependent (&gt;21 yrs of age 600mg daily (DIPG); &lt;21 yrs of age 350 mg/m2/day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-Biopsied Diffuse Instrinsic Pontine Glioma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ribociclib administered orally; daily on days 1-21 each 28 day cycle; dose calculation age dependent (&gt;21 yrs of age 600mg daily (DIPG); &lt;21 yrs of age 350 mg/m2/day)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribociclib</intervention_name>
    <arm_group_label>Non-Biopsied Diffuse Instrinsic Pontine Glioma</arm_group_label>
    <arm_group_label>RB+ High Grade Glioma</arm_group_label>
    <other_name>LEE011</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age&#xD;
&#xD;
               -  Patients must be ≥ 12 months of age and ≤ 30 years of age at the time of study&#xD;
                  entry for patients diagnosed with DIPG.&#xD;
&#xD;
               -  Patients must be ≥ 12 months of age and ≤ 21 years of age at the time of study&#xD;
                  entry for patients diagnosed with HGG.&#xD;
&#xD;
          -  RB status&#xD;
&#xD;
               -  Diagnostic stereotactic biopsy: Patients diagnosed with DIPG may choose to have a&#xD;
                  stereotactic biopsy prior to starting radiation therapy.&#xD;
&#xD;
               -  Toxicities related to biopsy must have resolved prior to proceeding with&#xD;
                  radiation therapy.&#xD;
&#xD;
               -  Screening for Rb applies to all patients with available tissue except for&#xD;
                  patients diagnosed with DIPG and bi-thalamic tumors.&#xD;
&#xD;
               -  If resection occurred at an outside institution, eligibility and treatment MRI&#xD;
                  evaluations in addition to Rb testing must be completed at CCHMC.&#xD;
&#xD;
          -  Tumor&#xD;
&#xD;
               -  Diffuse Intrinsic Pontine Glioma (DIPG) Patients with newly diagnosed diffuse&#xD;
                  intrinsic pontine gliomas (DIPGs), defined on neuroimaging as tumors with a&#xD;
                  pontine epicenter and diffuse intrinsic involvement of the pons, are eligible&#xD;
                  without histologic confirmation.&#xD;
&#xD;
               -  Patients with brainstem tumors that do not meet these criteria or not considered&#xD;
                  to be typical intrinsic pontine gliomas will only be eligible if the tumors are&#xD;
                  biopsied and proven to have + RB and be the following according to the 2016 World&#xD;
                  Health Organization classification of tumors of the central nervous system: an&#xD;
                  anaplastic astrocytoma (IDH mutant, IDH wildtype, or NOS), glioblastoma (IDH&#xD;
                  mutant, IDH wildtype or NOS), diffuse midline glioma, H3 K27M mutant or H3 K27M&#xD;
                  negative, diffuse astrocytoma (IDH mutant, IDH wildtype or NOS).&#xD;
&#xD;
               -  Note: Patients with juvenile pilocytic astrocytoma, pilomyxoid astrocytoma,&#xD;
                  pleomorphic xanthoastrocytoma with or without anaplasia, gangliogliomas, or other&#xD;
                  mixed gliomas without anaplasia are not eligible.&#xD;
&#xD;
               -  Patients with diffuse intrinsic brain stem glioma (DIPG) can be enrolled without&#xD;
                  the need for available tumor tissue for RB protein status confirmation.&#xD;
&#xD;
               -  Bi-thalamic tumors, biopsied and noted to have intact RB. Bi-thalamic tumors that&#xD;
                  are not biopsied will be eligible to enroll on the DIPG/bi-thalamic non-biopsied&#xD;
                  arm.&#xD;
&#xD;
               -  High-grade Glioma (HGG)&#xD;
&#xD;
               -  Patients must have had histologically verified the following according to the&#xD;
                  2016 World Health Organization classification of tumors of the central nervous&#xD;
                  system: anaplastic astrocytoma (IDH mutant, IDH wildtype, or NOS), glioblastoma&#xD;
                  multiforme (IDH mutant, IDH wildtype, or NOS), diffuse astrocytoma (IDH mutant,&#xD;
                  IDH wildtype or NOS)&#xD;
&#xD;
               -  AND RB positive noted on immunohistochemistry.&#xD;
&#xD;
               -  Patients with primary spinal cord tumors are eligible. Patients with multi-focal&#xD;
                  disease within the cerebrum are eligible.&#xD;
&#xD;
               -  Patients with a diagnosis of oligodendroglioma or oligoastrocytoma are not&#xD;
                  eligible.&#xD;
&#xD;
          -  Performance Status&#xD;
&#xD;
             • Karnofsky &gt; 50 % for patients &gt;16 years of age or Lansky &gt; 50 for patients &lt; 16&#xD;
             years of age. Patients who are unable to walk because of paralysis, but who are up in&#xD;
             a wheelchair, will be considered ambulatory for the purpose of assessing the&#xD;
             performance score.&#xD;
&#xD;
          -  Prior Therapy&#xD;
&#xD;
             • Patients must have not received any prior therapy other than surgery, radiation&#xD;
             and/or steroids.&#xD;
&#xD;
          -  Radiation therapy requirements&#xD;
&#xD;
               -  Patients diagnosed with DIPG: any variances in the radiotherapy dose within 10%&#xD;
                  of the current standard dose (54 Gy) will be discussed with the&#xD;
                  Sponsor-Investigator to confirm eligibility prior to study enrollment&#xD;
&#xD;
               -  Patients diagnosed with HGG: any variances in the radiotherapy dose within 10% of&#xD;
                  the current standard dose (59.4 Gy) will be discussed with the&#xD;
                  Sponsor-Investigator to confirm eligibility prior to study enrollment.&#xD;
&#xD;
               -  Patients diagnosed with primary spinal tumors any variances in the radiotherapy&#xD;
                  dose within 10% of the current standard dose (54 Gy) will be discussed with the&#xD;
                  Sponsor-Investigator to confirm eligibility prior to study enrollment.&#xD;
&#xD;
               -  Timing of Radiation - radiation therapy must begin no later than 30 days after&#xD;
                  the date of radiographic diagnosis or definitive surgery, whichever is the later&#xD;
                  date.&#xD;
&#xD;
          -  Organ Function&#xD;
&#xD;
               -  Patients must have normal organ and marrow function documented within 7 days of&#xD;
                  study enrollment as defined below:&#xD;
&#xD;
               -  Absolute neutrophil count ≥ 1000mm3&#xD;
&#xD;
               -  Platelets ≥ 75,000/mm3 (unsupported for 7 days)&#xD;
&#xD;
               -  Hemoglobin ≥ 9g/dl (unsupported) for 7 days&#xD;
&#xD;
               -  Total bilirubin ≤ 3 times upper limit of normal (ULN) for age&#xD;
&#xD;
               -  ALT (SGPT) ≤ 2.5 X ULN for age&#xD;
&#xD;
               -  Albumin ≥ 2 g/dl&#xD;
&#xD;
               -  Creatinine clearance or radioisotope GFR ≥ 70mL/min/1.73m2 or serum creatinine&#xD;
                  based on age/gender.&#xD;
&#xD;
          -  Pregnancy Status Female patients of childbearing potential, must not be pregnant or&#xD;
             breast-feeding. Female patients of childbearing potential must have a negative serum&#xD;
             or urine pregnancy test.&#xD;
&#xD;
          -  Pregnancy Prevention Patients of childbearing or child fathering potential must use a&#xD;
             highly effective method of contraception throughout the study while taking the drug&#xD;
             and for 21 days after stopping treatment&#xD;
&#xD;
          -  Female patients with infants must agree not to breastfeed their infants while on this&#xD;
             study.&#xD;
&#xD;
          -  Informed Consent Signed informed consent according to institutional guidelines must be&#xD;
             obtained. Assent, when appropriate, will be obtained according to institutional&#xD;
             guidelines.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concurrent Illness Patients with any clinically significant unrelated systemic illness&#xD;
             (serious infections or significant cardiac, pulmonary, hepatic or other organ&#xD;
             dysfunction) that would compromise the patient's ability to tolerate protocol therapy&#xD;
             or would likely interfere with the study procedures or results.&#xD;
&#xD;
          -  Inability to Participate Patients with inability to return for follow-up visits or&#xD;
             obtain follow-up studies required to assess toxicity to therapy.&#xD;
&#xD;
          -  Received a radiosensitizer or any additional adjuvant therapy during radiation&#xD;
             therapy.&#xD;
&#xD;
          -  Patients with disseminated disease to the spine are not eligible, and MRI of spine&#xD;
             must be performed prior to enrollment if the treating physician suspects disseminated&#xD;
             disease.&#xD;
&#xD;
          -  Seizures Patients who are currently receiving enzyme inducing anti-epileptic drugs&#xD;
             that are known strong inducers or inhibitors of CYP3A4/5 (EIAEDs). Patients with a&#xD;
             history of seizures and maintained on an anti-epileptic drug that is not a strong&#xD;
             inducers or inhibitor of CYP3A4/5 are eligible.&#xD;
&#xD;
          -  Patient has a known hypersensitivity to Ribociclib or any of its excipients.&#xD;
&#xD;
          -  Clinically significant active cardiac disease, uncontrolled heart disease and/or&#xD;
             history of cardiac dysfunction including any of the following&#xD;
&#xD;
               -  History of acute coronary syndromes (including myocardial infarction, unstable&#xD;
                  angina, coronary artery bypass grafting, coronary angioplasty, or stenting) or&#xD;
                  symptomatic pericarditis within 12 months prior to screening&#xD;
&#xD;
               -  History of documented congestive heart failure (New York Heart Association&#xD;
                  functional classification III-IV)&#xD;
&#xD;
               -  Documented cardiomyopathy&#xD;
&#xD;
               -  Patient has a Left Ventricular Ejection Fraction (LVEF) &lt; 50 % as determined by&#xD;
                  Multiple Gated acquisition (MUGA) scan or echocardiogram (ECHO) at screening&#xD;
&#xD;
               -  History of any cardiac arrhythmias, e.g., ventricular, supraventricular, nodal&#xD;
                  arrhythmias, or conduction abnormality within 12 months of screening&#xD;
&#xD;
               -  Long QT syndrome or family history of idiopathic sudden death or congenital long&#xD;
                  QT syndrome, or any of the following:&#xD;
&#xD;
               -  Risk factors for Torsades de Pointe (TdP) including uncorrected hypokalemia or&#xD;
                  hypomagnesemia, history of cardiac failure, or history of clinically&#xD;
                  significant/symptomatic bradycardia.&#xD;
&#xD;
               -  Concomitant use of medication(s) with a known risk to prolong the QT interval&#xD;
                  and/or known to cause Torsades de Pointe that cannot be discontinued (within 5&#xD;
                  half-lives or 7 days prior to starting study drug) or replaced by safe&#xD;
                  alternative medication&#xD;
&#xD;
               -  Hypertension defined below:&#xD;
&#xD;
               -  Patients 2-17 years of age must have a blood pressure that is ≤ 95th percentile&#xD;
                  for age, height and gender at the time of enrollment.&#xD;
&#xD;
               -  Patients who are ≥ 18 years of age must have a systolic blood pressure that is &gt;&#xD;
                  160 or diastolic &lt; 90 mm of Hg at the time of enrollment&#xD;
&#xD;
               -  Note: If a BP reading prior to enrollment is above the 95th percentile for age,&#xD;
                  height and gender, it is to be rechecked and documented to be ≤ 95th percentile&#xD;
                  for age, height and gender prior to patient enrollment.&#xD;
&#xD;
          -  Inability to determine the QTcF interval on the ECG (i.e. unreadable or not&#xD;
             interpretable) or QTcF &gt; 450 msec (using Fridericia's correction). All as determined&#xD;
             by screening ECG (using the mean QTcF of triplicate ECGs)&#xD;
&#xD;
          -  Patient is currently receiving any of the following medications and cannot be&#xD;
             discontinued 7 days prior to starting study drug Ribociclib:&#xD;
&#xD;
               -  Known strong inducers or inhibitors of CYP3A4/5, including grapefruit, grapefruit&#xD;
                  hybrids, pomelos, star-fruit, and Seville oranges&#xD;
&#xD;
               -  Medications that have a narrow therapeutic window and are predominantly&#xD;
                  metabolized through CYP3A4/5&#xD;
&#xD;
               -  Medications that have a known risk to prolong the QT interval or induce Torsades&#xD;
                  de Pointes&#xD;
&#xD;
               -  Herbal preparations/medications, dietary supplements.&#xD;
&#xD;
          -  Patient is currently receiving warfarin or other coumadin-derived anticoagulant for&#xD;
             treatment, prophylaxis or otherwise. Therapy with heparin, low molecular weight&#xD;
             heparin (LMWH) or fondaparinux is allowed&#xD;
&#xD;
          -  Patient has a history of non-compliance to medical regimen.&#xD;
&#xD;
          -  Known need for major surgery within 14 days of the first dose of Ribociclib.&#xD;
             Gastrostomy, insertion of a G tube, Ventriculo-peritoneal shunt, endoscopic&#xD;
             ventriculostomy and central venous access are NOT considered major surgery.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mariko DeWire, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>November 16, 2015</study_first_submitted>
  <study_first_submitted_qc>November 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2015</study_first_posted>
  <results_first_submitted>August 27, 2020</results_first_submitted>
  <results_first_submitted_qc>October 15, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 5, 2020</results_first_posted>
  <last_update_submitted>October 15, 2020</last_update_submitted>
  <last_update_submitted_qc>October 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DIPG</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Diffuse Intrinsic Pontine Glioma</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 27, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/24/NCT02607124/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Non-Biopsied Diffuse Instrinsic Pontine Glioma/Diffuse Midline Glioma</title>
          <description>Ribociclib administered orally; daily on days 1-21 each 28 day cycle; dose calculation age dependent (&gt;21 yrs of age 600mg daily (DIPG); &lt;21 yrs of age 350 mg/m2/day)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10">11 participants were enrolled however 1 participant withdrew before starting study treatment.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Demographics for participants are combined for enrolled participants stratified by diagnosis. Intervention was identical for all diagnoses.</population>
      <group_list>
        <group group_id="B1">
          <title>Diffuse Instrinsic Pontine Glioma and Diffuse Midline Glioma</title>
          <description>Ribociclib administered orally; daily on days 1-21 each 28 day cycle; dose calculation age dependent (&gt;21 yrs of age 600mg daily (DIPG); &lt;21 yrs of age 350 mg/m2/day)&#xD;
Baseline characteristics data are collected irrespective of Arm/Group and cannot be reported separately.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>One enrolled participant was ineligible for study treatment and removed from trial therefore deemed inevaluable.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.5" lower_limit="3.8" upper_limit="20.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Adverse Events</title>
        <description>Primary feasibility endpoint is the number of individual toxicities and incidence of significant delays</description>
        <time_frame>6 months</time_frame>
        <population>Number of participants receiving investigational agent.</population>
        <group_list>
          <group group_id="O1">
            <title>RB+ High Grade Glioma</title>
            <description>Ribociclib administered orally; daily on days 1-21 each 28 day cycle; dose calculation age dependent (&gt;21 yrs of age 600mg daily (DIPG); &lt;21 yrs of age 350 mg/m2/day)&#xD;
Ribociclib</description>
          </group>
          <group group_id="O2">
            <title>Non-Biopsied Diffuse Instrinsic Pontine Glioma</title>
            <description>Ribociclib administered orally; daily on days 1-21 each 28 day cycle; dose calculation age dependent (&gt;21 yrs of age 600mg daily (DIPG); &lt;21 yrs of age 350 mg/m2/day)&#xD;
Ribociclib</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Adverse Events</title>
          <description>Primary feasibility endpoint is the number of individual toxicities and incidence of significant delays</description>
          <population>Number of participants receiving investigational agent.</population>
          <units>adverse event</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Alive at One Year</title>
        <time_frame>1 year</time_frame>
        <population>Number of enrolled and evaluable participants</population>
        <group_list>
          <group group_id="O1">
            <title>RB+ High Grade Glioma</title>
            <description>Ribociclib administered orally; daily on days 1-21 each 28 day cycle; dose calculation age dependent (&gt;21 yrs of age 600mg daily (DIPG); &lt;21 yrs of age 350 mg/m2/day)&#xD;
Ribociclib</description>
          </group>
          <group group_id="O2">
            <title>Non-Biopsied Diffuse Instrinsic Pontine Glioma</title>
            <description>Ribociclib administered orally; daily on days 1-21 each 28 day cycle; dose calculation age dependent (&gt;21 yrs of age 600mg daily (DIPG); &lt;21 yrs of age 350 mg/m2/day)&#xD;
Ribociclib</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Alive at One Year</title>
          <population>Number of enrolled and evaluable participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <desc>Adverse events grades 1 and 2 that are at least possibly related to ribociclib and all adverse events grades 3 and higher regardless of attribution during study treatment were recorded for the purposes of safety monitoring.&#xD;
There were no serious adverse events attributable to study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Diffuse Intrinsic Pontine Glioma and High Grade Glioma</title>
          <description>Ribociclib administered orally; daily on days 1-21 each 28 day cycle; dose calculation age dependent (&gt;21 yrs of age 600mg daily (DIPG); &lt;21 yrs of age 350 mg/m2/day)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Gait Disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Non Cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection-Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Accessory nerve disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nervous system disorders - Other, specify (hemiparesis)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pyramidal tract syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Reversible posterior leukoencephalopathy syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>agitation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>hallucination</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders - Other, specify (tachypnea)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Gastroesophageal reflux diease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Gait Disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Creatinine Increased</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Ejection fraction decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT corrected interval prolonged</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Lymphocyte Count Decreased</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Neutrophil Count Decreased</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Platelet Count Decreased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Weight Gain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Weight Loss</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>White Blood Cell Decreased</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorder - Other, specify (Osteonecrosis - hip)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Irregular menstruation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Sore throat</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Other - Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Other - petechial rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Renee Doughman</name_or_title>
      <organization>Cincinnati Childrens Hosptial Medical Center</organization>
      <phone>513-636-1699</phone>
      <email>renee.doughman@cchmc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

